bioRxiv preprint doi: https://doi.org/10.1101/2021.04.14.436660; this version posted April 15, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Germline variants that influence the tumor immune microenvironment also drive response to immunotherapy Authors: Meghana Pagadala1, Victoria H. Wu4, Eva Pérez-Guijarro12, Hyo Kim15, Andrea Castro2, James Talwar2, Cristian Gonzalez-Colin3, Steven Cao5, Benjamin J. Schmiedel3, Rany M. Salem5, Gerald P. Morris6, Olivier Harismendy7,10, Sandip Pravin Patel8, Jill P. Mesirov9,10, Maurizio Zanetti10,11, Chi-Ping Day12, Chun Chieh Fan13, Wesley K. Thompson14, Glenn Merlino12, J. Silvio Gutkind4, Pandurangan Vijayanand3, Hannah Carter9,10,* *Correspondence to:
[email protected] Affiliations: 1Biomedical Science Program, University of California San Diego, La Jolla, CA 92093, USA 2Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, CA, 92093, USA 3La Jolla Institute for Immunology, La Jolla, CA, 92037, USA 4Department of Pharmacology, UCSD Moores Cancer Center, La Jolla, CA, 92093, USA 5Division of Epidemiology, Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, 92093, USA 6Department of Pathology, University of California San Diego, La Jolla, CA 92093, USA 7Division of Biomedical Informatics, Department of Medicine, University of California San Diego School of Medicine, La Jolla,